GlassScriptPhysician profile
Jackqulyn Brown
NPI 1194591719
$2,277.84
in general payments reported to CMS, 2019-2025
16 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $37.74 · 2024: $944 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $777.35 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $291.27 | 2024-2025 | Kisunla, Mounjaro, Zepbound |
| Amgen INC. | $258.87 | 2024-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $246.34 | 2024-2025 | |
| Glaxosmithkline, LLC. | $167.42 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $133.49 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $97.50 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $72.29 | 2025 | |
| Pfizer INC. | $60.31 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $45.22 | 2025 | Gemtesa |
| Gilead Sciences, INC. | $37.09 | 2025 | |
| Corcept Therapeutics | $25.84 | 2025 | Korlym |
| Dexcom, INC. | $19.44 | 2024 | Dexcom G6 Transmitter |
| Abiomed | $18.14 | 2023 | Impella |
| Astellas Pharma US INC | $14.02 | 2024 | Veozah |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $13.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackqulyn Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.